B350vsCP250: Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma

• Sponsor: State University of New York at Buffalo (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04542616
• Collaborator: (none)
• Enrollment: 70
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 48.6
• Patients Per Site Per Month: 1.4

Study Details

Study Description

Brief Summary

To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.

Condition or Disease	Intervention/Treatment	Phase
Glaucoma	Device: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation	N/A

Detailed Description

Tube shunt implantation is a common type of surgery considered standard of care for treating significant potentially-blinding glaucoma where medical and laser treatment, and previous surgeries, have failed to control intra-ocular pressure (IOP) sufficiently to stop glaucoma progression towards blindness.

Since a larger plate tube (e.g., Baerveldt 350) is more difficult to implant requiring longer surgical time and intraoperative ocular muscle manipulation with possible patient discomfort, a smaller plate tube shunt (e.g., Ahmed ClearPath 250) requiring shorter surgical time and no ocular muscle manipulation may have an advantage if the long term surgical outcomes were the same.

However, the literature is lacking regarding the effect of the tube plate size on the final outcomes of tube shunt implantation. Most published comparisons are between totally different types of tube shunts regardless of plate size, often made of different materials, often comparing valved vs. non-valved tube shunts,combining different plate sizes in the same study groups,5 mixing tubes with or without combined cataract surgery in the same study groups, or comparing surgeries performed by several surgeons utilizing different surgical methods. Further, all these studies utilize tubes implanted into the anterior chamber (AC) thus increasing the risk of corneal failure, with no comparisons at all between tube shunts implanted through the ciliary sulcus of the eye designed to reduce the risk of corneal failure. Our Principle Investigator (AW) is specializing and well-published in this type of tube shunt implantation.

This prospective randomized trial is designed to resolve all these confusing factors in the literature and finally provide the answer of whether tube plate size has an effect on the final outcomes of tube shunt implantation by performing a "clean" study that would isolate the effect of tube plate size on long term outcomes. To achieve this goal our study will utilize two non-valved tube shunts with a different plate size (350 vs. 250 mm2) made of identical materials, in eyes that have already had cataract surgery, and all performed by the same surgeon (AW) through the ciliary sulcus.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 70 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Comparison between 2 groups of patients requiring tube shunt implantation to treat their severe uncontrolled glaucoma. One group will receive a unilateral Baerveldt 350 tube shunt and the other a unilateral Ahmed ClearPath 250 tube shunt. The patients will be sequentially randomized into one of these tube shunts.Comparison between 2 groups of patients requiring tube shunt implantation to treat their severe uncontrolled glaucoma. One group will receive a unilateral Baerveldt 350 tube shunt and the other a unilateral Ahmed ClearPath 250 tube shunt. The patients will be sequentially randomized into one of these tube shunts.
• Masking: Single (Outcomes Assessor)
• Masking Description: All patients will sign a consent form indicating they will be randomly receiving one of the 2 tube shunt models. It would be impossible to mask the patient or care provider to the type of tube shunt a patient received. The patients cannot bias the clinical data recorded on their follow up exams. All data will be recorded objectively. The outcome assessor will be masked to the type of shunt used.
• Primary Purpose: Treatment
• Official Title: Outcomes Comparison Between Baerveldt 350 and Ahmed ClearPath 250 Tube Shunts for the Treatment of Glaucoma
• Actual Study Start Date: Aug 13, 2020
• Anticipated Primary Completion Date: Aug 31, 2023
• Anticipated Study Completion Date: Aug 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Baerveldt 350 The patients in this arm will receive a Baerveldt 350 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.	Device: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation; Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
Active Comparator: Ahmed ClearPath 250 The patients in this arm will receive an Ahmed ClearPath 250 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.	Device: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation; Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.

Outcome Measures

Primary Outcome Measures

1. Change in intraocular pressure [2 years]

   Change in Intraocular pressure between preoperative baseline and postoperative follow-up visits

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Significant uncontrolled glaucoma despite medical, laser or previous surgical therapy that requires tube shunt implantation as standard-of-care to stabilize the glaucoma and preserve vision.

• Pseudophakia

• Patients who are willing to participate and are able to understand and sign the study consent form.

• Age ≥18 years.

Exclusion Criteria:

• Phakic eyes (no previous cataract surgery).

• Aphakic eyes (status post previous cataract removal but without a lens implant).

• Age <18 years.

• Women of child-bearing age.

• Patients unable to comprehend and sign the study consent form.

• Women who are pregnant.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Ira G. Ross Eye Institute	Buffalo	New York	United States	14209

Sponsors and Collaborators

• State University of New York at Buffalo

Investigators

• Principal Investigator: Asher Weiner, MD, The Ross Eye Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Asher Weiner, Clinical Associate Professor, State University of New York at Buffalo
• ClinicalTrials.gov Identifier: NCT04542616
• Other Study ID Numbers: STUDY00004680
• First Posted: Sep 9, 2020
• Last Update Posted: Sep 28, 2021
• Last Verified: Sep 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Keywords provided by Asher Weiner, Clinical Associate Professor, State University of New York at Buffalo: Glaucoma; Baerveldt 350; Ahmed ClearPath 250
• Additional relevant MeSH terms: Glaucoma

Study Results

No Results Posted as of Sep 28, 2021